We’re excited to announce that Siren’s community round is officially open to the public! 🎉

Today, we’re opening a door that’s rarely opened in the therapeutics space. For the first time ever, anyone can invest in Siren right alongside top institutional backers like Founders Fund, Lux Capital, and Innovation Endeavors.

Siren Biotechnology is pioneering a bold new approach to treating cancer. Our platform uses a safe, engineered virus to deliver immune-activating medicine directly to tumors – with the goal of treating multiple types of cancer with more precision, fewer side effects, and broader impact. 🧬

With $28M+ raised, $4M+ in grant funding, and a world-class team from UCSF, Stanford, Duke, and beyond, we’re preparing for our first clinical trials. We’re building toward a future where this therapy could bring hope to millions and we want you there with us. 

We opened this round because we believe innovation in cancer care shouldn’t be limited to big investors. This round is for you — patients, families, doctors, scientists, and believers who care deeply about what comes next. 

NOW is your chance to be part of the next biotech breakthrough, from the ground floor.

💸 Invest Now 

Together, we can change what cancer treatment looks like forever ❤️

With gratitude,

Dr. Nicole K. Paulk, PhD

CEO, Founder, and President